Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jardiance in Heart Failure with Preserved Ejection Fraction (EMPERIAL-Preserved)
NCT03448406Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of empagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Boehringer Ingelheim. Started Mar 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03448406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03448406.